Opioid Mortality Following Implementation of Medical Cannabis Programs in the United States

Abstract

Introduction The United States is in the midst of an opioid overdose epidemic. Emerging evidence suggests that medical cannabis (MC) may reduce use of opioids for pain in some individuals, with potential impacts on opioid-related overdose. However, there may be other important differences between states that did, and did not, adopt MC.

Methods This study evaluated differences following legal MC sales on US opioid-related overdose deaths, corrected for population, from 1999 to 2017 using an interrupted time series. Comparisons by MC status were also made for Medicaid expansion and the Centers for Disease Control death certificate reporting quality (0: <good, 1: good, 2: excellent).

Results Overdose deaths were significantly higher in MC states from 2012–2017. Overdose death slopes over time increased in states with (pre=1.46±0.46, post=2.90±0.58, p<0.05) and without (pre =0.20±.10, post=1.04±0.22, p<0.005) MC. Post-legalization slopes were significantly higher in MC states (p<0.01). Two states without (11.1%) as compared to 11 states with (91.7%) MC expanded Medicaid by 2014 (χ²[1]=19.03, p<0.0005). MC states (1.50±0.23) had higher death certificate reporting quality relative to states without MC (0.78±0.22, p<0.05).

Discussion MC states had higher rates of opioid overdoses. Although there was no decrease in association with MC introduction, these results were confounded by states without MC having lower overdose reporting quality. Medicaid expansion was also more common in states with MC. Finally, the potency of fentanyl analogues may have obscured any protective effects of MC against illicit opioid harms.

Publikationsverlauf

Eingereicht: 21. Juni 2020
Eingereicht: 09. Dezember 2020

Angenommen: 04. Januar 2021

Artikel online veröffentlicht:
23. Februar 2021

• References

• 1 Reuben DB, Alvanzo AA, Ashikaga T. et al. National Institutes of Health pathways to prevention workshop: the role of opioids in the treatment of chronic pain. Ann Intern Med 2015; 162: 295-300
• 2 Seth P, Scholl L, Rudd RA. et al. Deaths involving opioids, cocaine, and psychostimulants – United States, 2015–2016. MMWR Morb Mortal Wkly Rep 2018; 67: 349-358
• 3 Ahmad FB, Escobedo LA, Rossen LM. et al. Provisional drug overdose death counts. National Center for Health Statistics. 2019; accessed 3/26/20 at https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
• 4 Buchanich JM, Balmert LC, Williams KE. et al. The effect of incomplete death certificates on estimates of unintentional opioid-related overdose deaths in the United States, 1999–2015. Public Health Rep 2018; 133: 423-431.
• 5 Rudd RA, Seth P, David F. et al. Increases in drug and opioid-involved overdose deaths - United States, 2010–2015. MMWR Morb Mortal Wkly Rep 2016; 65: 1445-1452.
• 6 Piper BJ, Shah DT, Simoyan OM. et al. Trends in medical use of opioids in the U.S., 2006–2016. Am J Prev Med 2018; 54: 652-660
• 7 Pashmineh Azar AR, Cruz-Mullane A, Podd JC. et al. Rise and regional disparities in buprenorphine utilization in the United States. Pharmacoepidiol Drug Saf 2020;
• 8 Schwartz RP, Grycznski J, O’Grady KE. et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am J Pub Health 2013; 103: 917-922
• 9 Wen H, Hockenberry JM, Borders TF. et al. Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment. Med Care 2017; 55: 336-341.
• 10 Smith FL, Cichewicz D, Martin ZL. et al. The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. Pharmacol Biochem Behav 1998; 60: 559-566 PMID: 9632241
• 11 Abrams DI, Couey P, Shade SB. et al. Cannabinoid–opioid interaction in chronic pain. Clin Pharmacol Ther 2011; 90: 844-851
• 12 Piper BJ, DeKeuster RM, Beals ML. et al. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacology 2017; 31: 569-575
• 13 Stith SS, Vigil JM, Adams IM. et al. Effects of legal access to cannabis on scheduled II-V drug prescriptions. J Am Med Dir Assoc 2018; 19: 59-64.e1
• 14 Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Affairs 2016; 35: 1230-1236.
• 15 National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence .and Recommendations for Research. Washington, DC: The National Academies Press; 2017
• 16 Bachhuber MA, Saloner B, Cunningham CO. et al. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med 2014; 174: 1875
• 17 Shover CL, Davis CS, Gordon SC. et al. Association between medical cannabis and opioid overdose mortality has reversed. Proc Natl Acad Sci USA 2019; 116: 12624-12626
• 18 Shi Y. Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend 2017; 173: 144-150
• 19 Powell D, Pacula RL, Jacobson M.. Do medical marijuana laws reduce addictions and deaths related to pain killers?. J Health Econ 2018; 58: 29-42
• 20 Centers for Disease Control and Prevention. CDC WONDER Accessed 3/26/20 at https://wonder.cdc.gov/
• 21 Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Aff 2017; 36: 945-951
• 22 Simpson KJ, Moran MT, Foster ML. et al. Descriptive, observational study of pharmaceutical and non-pharmaceutical arrests, use, and overdoses in Maine. BMJ Open 2019; 9: e027117.
• 23 Kroenke K, Cheville A. Management of chronic pain in the aftermath of the opioid backlash. JAMA 2017; 317: 2365-2366
• 24 Mercurio A, Aston ER, Claborn KR. et al. Marijuana as a substitute for prescription medications: A qualitative study. Subst Use Misuse 2019; 54: 1894-1902